Paratek is developing the antibiotic further in a phase 2 study to evaluate the safety, tolerability and pharmacokinetics of NUZYRA™ in female patients with uncomplicated UTI which is currently in progress (NCT03425396).

Under a research agreement with the U.S. Department of Defense NUZYRA™ is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.

Paratek owns world-wide rights to omadacycline. Paratek has entered into a collaboration with Zai Lab (Shanghai) Co., Ltd., a biopharmaceutical company based in China, to support the development and commercialization of omadacycline for patients in Greater China. Paratek is open to discussing partnerships for rights in other regions with interested parties. Please contact us here.



Saracycline is an investigational antibiotic for the proposed treatment of moderate to severe acne vulgaris in patients nine years of age and older.

A New Drug Application for sarecycline is currently under review by the U.S. Food & Drug Administration based on the positive results of two identical Phase 3 registration studies. If approved, sarecycline will be commercialized by Allergan in the U.S.

Paratek has retained rest of world (outside of the U.S.) rights to sarecycline and is currently exploring partnership opportunities to develop and approve sarecycline in appropriate markets.